

PRECEPT

Panitumumab Regimen Evaluation in Colorectal cancer to Estimate Primary response to Treatment

Have you or has someone you know been previously treated for metastatic colorectal cancer?

If **SO**, there is a nationwide research study for metastatic colorectal cancer involving an investigational drug called panitumumab given with standard chemotherapy.

This study is designed to see who may best benefit from treatment with panitumumab and standard chemotherapy. This study is called **PRECEPT** and is being sponsored by AMGEN.

Participants in this study may help future metastatic colorectal cancer patients benefit from what is learned from this study.

To learn more about this study, call 1-866-57 AMGEN (866-572-6436) today and ask about the **PRECEPT** study. Or visit www.clinicaltrials.gov or www.amgentrials.com

AMGEN[®]